{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:11:26Z","timestamp":1786983086055,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T00:00:00Z","timestamp":1639267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T00:00:00Z","timestamp":1639267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early-onset androgenic alopecia is considered the phenotypic equivalent of\u00a0polycystic ovary\u00a0syndrome in men. The purpose of the current study was to investigate whether the presence of early-onset male-pattern baldness modulates metabolic effects of metformin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective case\u2013control study included 2 groups of men at high risk for type 2 diabetes: 72 individuals with androgenic alopecia (group A) and 75 subjects with normal hair growth (group B). Both groups were matched for age, blood pressure, body mass index, insulin sensitivity and plasma lipids. Glycated hemoglobin, glucose, plasma lipids, indices of insulin sensitivity\/resistance, sex hormones, high-sensitivity C-reactive protein (hsCRP) and 25-hydroxyvitamin D were determined before and after metformin treatment (1.7\u00a0g daily).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity. Although observed in both study populations, these effects were more pronounced in group B. Moreover, metformin decreased hsCRP and bioavailable testosterone levels in group B, as well as reduced 25-hydroxyvitamin D concentration in group A. Treatment-induced changes in glucose homeostasis markers correlated with the impact of metformin on hsCRP and 25-hydroxyvitamin D levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metabolic effects of metformin in males are attenuated if they have coexisting early-onset androgenic alopecia. This finding may be partially explained by differences in severity of low-grade systemic inflammation and vitamin D status. The obtained results, requiring confirmation in large prospective studies, suggest that men with early-onset male-pattern baldness benefit to a lesser degree from metformin treatment than other men at high risk for type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-021-00347-8","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T02:02:21Z","timestamp":1639274541000},"page":"216-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impaired metabolic effects of metformin in men with early-onset androgenic alopecia"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-2620","authenticated-orcid":false,"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Kowalcze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,12]]},"reference":[{"key":"347_CR1","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-016-0629-5","volume":"76","author":"Y Kelly","year":"2016","unstructured":"Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016;76:1349\u201364.","journal-title":"Drugs"},{"key":"347_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-017-1280-y","volume":"57","author":"F Lolli","year":"2017","unstructured":"Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57:9\u201317.","journal-title":"Endocrine"},{"key":"347_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0738-081X(00)00128-0","volume":"19","author":"RD Sinclair","year":"2001","unstructured":"Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol. 2001;19:167\u201378.","journal-title":"Clin Dermatol"},{"key":"347_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40618-017-0728-5","volume":"41","author":"R Cannarella","year":"2018","unstructured":"Cannarella R, Condorelli RA, Mongio\u00ec LM, La Vignera S, Calogero AE. Does a male polycystic ovarian syndrome equivalent exist? J Endocrinol Invest. 2018;41:49\u201357.","journal-title":"J Endocrinol Invest"},{"key":"347_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/ijdvl.IJDVL_262_17","volume":"84","author":"L Martinez-Jacobo","year":"2018","unstructured":"Martinez-Jacobo L, Villarreal-Villarreal CD, Ortiz-L\u00f3pez R, Ocampo-Candiani J, Rojas-Mart\u00ednez A. Genetic and molecular aspects of androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2018;84:263\u20138.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"347_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1046\/j.1523-1747.2001.01261.x","volume":"116","author":"JA Ellis","year":"2001","unstructured":"Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116:452\u20135.","journal-title":"J Invest Dermatol"},{"key":"347_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamadermatol.2016.1776","volume":"152","author":"S Sanke","year":"2016","unstructured":"Sanke S, Chander R, Jain A, Garg T, Yadav P. A comparison of the hormonal profile of early androgenetic alopecia in men with the phenotypic equivalent of polycystic ovarian syndrome in women. JAMA Dermatol. 2016;152:986\u201391.","journal-title":"JAMA Dermatol"},{"key":"347_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s43440-020-00135-w","volume":"73","author":"R Krysiak","year":"2021","unstructured":"Krysiak R, Szkr\u00f3bka W, Okopie\u0144 B. The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome. Pharmacol Rep. 2021;73:261\u20138.","journal-title":"Pharmacol Rep"},{"key":"347_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1684\/ejd.2010.1193","volume":"21","author":"C Mumcuoglu","year":"2011","unstructured":"Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol. 2011;21:79\u201382.","journal-title":"Eur J Dermatol"},{"key":"347_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.mehy.2017.04.010","volume":"103","author":"PR Cohen","year":"2017","unstructured":"Cohen PR, Kurzrock R. Polycystic ovary syndrome in men. Med Hypotheses. 2017;103:64.","journal-title":"Med Hypotheses"},{"key":"347_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.mehy.2006.03.057","volume":"68","author":"R Kurzrock","year":"2007","unstructured":"Kurzrock R, Cohen PR. Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. Med Hypotheses. 2007;68:480\u20133.","journal-title":"Med Hypotheses"},{"key":"347_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jamadermatol.2013.130","volume":"149","author":"LH Su","year":"2013","unstructured":"Su LH, Chen LS, Lin SC, Chen HH. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. JAMA Dermatol. 2013;149:601\u20136.","journal-title":"JAMA Dermatol"},{"key":"347_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ijcard.2014.07.079","volume":"176","author":"N Trieu","year":"2014","unstructured":"Trieu N, Eslick GD. Alopecia and its association with coronary heart disease and cardiovascular risk factors: a meta-analysis. Int J Cardiol. 2014;176:687\u201395.","journal-title":"Int J Cardiol"},{"key":"347_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clindermatol.2017.09.013","volume":"36","author":"MM Roth","year":"2018","unstructured":"Roth MM, Leader N, Kroumpouzos G. Gynecologic and andrologic dermatology and the metabolic syndrome. Clin Dermatol. 2018;36:72\u201380.","journal-title":"Clin Dermatol"},{"key":"347_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clindermatol.2017.09.009","volume":"36","author":"C Lie","year":"2018","unstructured":"Lie C, Liew CF, Oon HH. Alopecia and the metabolic syndrome. Clin Dermatol. 2018;36:54\u201361.","journal-title":"Clin Dermatol"},{"key":"347_CR16","first-page":"597","volume":"43","author":"DX Wu","year":"2014","unstructured":"Wu DX, Wu LF, Yang ZX. Association between androgenetic alopecia and metabolic syndrome: a meta-analysis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014;43:597\u2013601.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"347_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/01.hjh.0000202813.79964.4a","volume":"24","author":"M Clemenz","year":"2006","unstructured":"Clemenz M, Kintscher U, Unger T. The metabolic syndrome: cluster with a self-fulfilling loop? J Hypertens. 2006;24:257\u20138.","journal-title":"J Hypertens"},{"key":"347_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21101\/cejph.b0045","volume":"14","author":"P Hirsso","year":"2006","unstructured":"Hirsso P, Laakso M, Matilainen V, Hiltunen L, Rajala U, Jokelainen J, et al. Association of insulin resistance linked diseases and hair loss in elderly men. Finnish population-based study. Cent Eur J Public Health. 2006;14:78\u201381.","journal-title":"Cent Eur J Public Health"},{"key":"347_CR19","first-page":"127","volume":"39","author":"L Starka","year":"2005","unstructured":"Starka L, Duskova M, Cermakova I, Vrbikov\u00e1 J, Hill M. Premature\u00a0androgenic\u00a0alopecia\u00a0and insulin resistance. Male equivalent of polycystic ovary syndrome? Endocr Regul. 2005;39:127\u201331.","journal-title":"Endocr Regul."},{"key":"347_CR20","doi-asserted-by":"crossref","unstructured":"Chen L, Chen R, Wang H, Liang F. Mechanisms linking\u00a0inflammation\u00a0to\u00a0insulin\u00a0resistance. Int J Endocrinol 2015; p. 508409","DOI":"10.1155\/2015\/508409"},{"key":"347_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/physrev.00033.2011","volume":"93","author":"A Tchernof","year":"2013","unstructured":"Tchernof A, Despr\u00e9s JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359\u2013404.","journal-title":"Physiol Rev"},{"key":"347_CR22","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/molecules26102844","volume":"26","author":"R Krysiak","year":"2021","unstructured":"Krysiak R, Basiak M, Okopie\u0144 B. Cardiometabolic risk factors in rosuvastatin-treated men with mixed dyslipidemia and early-onset androgenic alopecia. Molecules. 2021;26:2844.","journal-title":"Molecules"},{"key":"347_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF03256589","volume":"8","author":"GM Keating","year":"2008","unstructured":"Keating GM, Robinson DM. Rosuvastatin: a review of its effect on atherosclerosis. Am J Cardiovasc Drugs. 2008;8:127\u201346.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"Suppl 1","key":"347_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/ajhp\/57.suppl_1.S3","volume":"57","author":"RW Piepho","year":"2000","unstructured":"Piepho RW. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000;57(Suppl 1):S3-7.","journal-title":"Am J Health Syst Pharm"},{"key":"347_CR25","doi-asserted-by":"publisher","first-page":"e738","DOI":"10.1097\/FJC.0000000000001113","volume":"78","author":"R Krysiak","year":"2021","unstructured":"Krysiak R, Basiak M, Okopie\u0144 B. Impact of lisinopril on cardiometabolic risk factors in men with hypertension and early-onset androgenetic alopecia: a pilot study. J Cardiovasc Pharmacol. 2021;78:e738\u201342.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 1","key":"347_CR26","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes \u2013 2021. Diabetes Care. 2021;44(Suppl 1):S111\u201324.","journal-title":"Diabetes Care"},{"key":"347_CR27","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1007\/s00125-017-4335-y","volume":"60","author":"JC Florez","year":"2017","unstructured":"Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017;60:1648\u201355.","journal-title":"Diabetologia"},{"key":"347_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1464-5491.1999.00090.x","volume":"16","author":"CL Li","year":"1999","unstructured":"Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16:477\u201381.","journal-title":"Diabet Med"},{"key":"347_CR29","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1007\/s11606-019-05238-6","volume":"34","author":"T Moin","year":"2019","unstructured":"Moin T, Duru OK, Turk N, Chon JS, Frosch DL, Martin JM, et al. Effectiveness of shared decision-making for diabetes prevention: 12-monthresults from the Prediabetes Informed Decision and Education (PRIDE) Trial. J Gen Intern Med. 2019;34:2652\u20139.","journal-title":"J Gen Intern Med"},{"key":"347_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"Diabetes Prevention Program. Research Group","year":"2002","unstructured":"Diabetes Prevention Program. Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393\u2013403.","journal-title":"N Engl J Med"},{"key":"347_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/00007611-197511000-00009","volume":"68","author":"OT Norwood","year":"1975","unstructured":"Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68:1359\u201365.","journal-title":"South Med J"},{"key":"347_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1749-6632.1951.tb31971.x","volume":"53","author":"JB Hamilton","year":"1951","unstructured":"Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53:708\u201328.","journal-title":"Ann N Y Acad Sci"},{"key":"347_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5507\/bp.2019.021","volume":"163","author":"S Placzkowska","year":"2019","unstructured":"Placzkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A. Indirect insulin resistance detection: current clinical trends and laboratory limitations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019;163:187\u201399.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"347_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/2230-8210.146874","volume":"19","author":"M Gutch","year":"2015","unstructured":"Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity\/resistance. Indian J Endocrinol Metab. 2015;19:160\u20134.","journal-title":"Indian J Endocrinol Metab"},{"key":"347_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1196\/annals.1365.015","volume":"1092","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci. 2006;1092:175\u201386.","journal-title":"Ann N Y Acad Sci"},{"key":"347_CR36","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s43032-020-00369-2","volume":"28","author":"Y Mu","year":"2021","unstructured":"Mu Y, Cheng D, Yin TL, Yang J. Vitamin D and polycystic ovary syndrome: a narrative review. Reprod Sci. 2021;28:2110\u20137.","journal-title":"Reprod Sci"},{"key":"347_CR37","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793\u2013801.","journal-title":"J Clin Invest"},{"key":"347_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jsbmb.2016.09.017","volume":"175","author":"SJ Wimalawansa","year":"2018","unstructured":"Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol. 2018;175:177\u201389.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"347_CR39","first-page":"694","volume":"68","author":"DM Khan","year":"2018","unstructured":"Khan DM, Jamil A, Randhawa FA, Butt NF, Malik U. Efficacy of oral vitamin D on glycated haemoglobin (HbA1c) in type 2 diabetics having vitamin D deficiency - a randomized controlled trial. J Pak Med Assoc. 2018;68:694\u20137.","journal-title":"J Pak Med Assoc"},{"key":"347_CR40","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1002\/jcp.26300","volume":"233","author":"SN Amin","year":"2018","unstructured":"Amin SN, Hussein UK, Yassa HD, Hassan SS, Rashed LA. Synergistic actions of vitamin D and metformin on skeletal muscles and insulin resistance of type 2 diabetic rats. J Cell Physiol. 2018;233:5768\u201379.","journal-title":"J Cell Physiol"},{"key":"347_CR41","doi-asserted-by":"publisher","first-page":"e100379","DOI":"10.1371\/journal.pone.0100379","volume":"9","author":"Q Liu","year":"2014","unstructured":"Liu Q, Li S, Quan H, Li J. Vitamin\u00a0B12\u00a0status in\u00a0metformin\u00a0treated patients: systematic review. PLoS ONE. 2014;9:e100379.","journal-title":"PLoS ONE"},{"key":"347_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ceb.2017.01.005","volume":"45","author":"D Carling","year":"2017","unstructured":"Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol. 2017;45:31\u20137.","journal-title":"Curr Opin Cell Biol"},{"key":"347_CR43","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577\u201385.","journal-title":"Diabetologia"},{"key":"347_CR44","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1440-1681.12409","volume":"42","author":"HX Li","year":"2015","unstructured":"Li HX, Gao JM, Liang JQ, Xi JM, Fu M, Wu YJ. Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK\/mTOR signalling pathway. Clin Exp Pharmacol Physiol. 2015;42:711\u20137.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"347_CR45","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jsbmb.2019.04.008","volume":"190","author":"BG Keevil","year":"2019","unstructured":"Keevil BG, Adaway J. Assessment of free testosterone concentration. J Steroid Biochem Mol Biol. 2019;190:207\u201311.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"347_CR46","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1530\/JOE-12-0455","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217:R25-45.","journal-title":"J Endocrinol"},{"key":"347_CR47","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.sxmr.2018.12.004","volume":"7","author":"G Hackett","year":"2019","unstructured":"Hackett G. Metabolic effects of testosterone therapy in men with type 2 diabetes and metabolic syndrome. Sex Med Rev. 2019;7:476\u201390.","journal-title":"Sex Med Rev"},{"key":"347_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000134751","volume":"13","author":"WL Miller","year":"2008","unstructured":"Miller WL. Steroidogenic enzymes. Endocr Dev. 2008;13:1\u201318.","journal-title":"Endocr Dev"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00347-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00347-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00347-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:17:19Z","timestamp":1676063839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00347-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,12]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00347-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,12]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Medical University of Silesia institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional approval"}}]}}